A new trial will evaluate whether integrating autonomous AI screening for diabetic retinopathy into U.S. federally qualified health centers can boost screening completion and accelerate early detection. The DRES-POCAI protocol tests a real-world, point-of-care model that links FDA-cleared AI with electronic health records to close gaps in diabetes eye care.